# E. COLI PATHOTYPES: COMPREHENSIVE CLASSIFICATION & TREATMENT GUIDE ## Clinical Reference for Physicians ------------------------------------------------------------------------ ## TABLE 1: E. COLI PATHOTYPES - CLASSIFICATION & ANTIBIOTIC TREATMENT | **Abbreviation** | **Full Name** | **Primary Disease(s)** | **Key Clinical Features** | **Antibiotic Treatment** | **Treatment Rationale** | |----|----|----|----|----|----| | **STEC** / **EHEC** | Shiga Toxin-Producing E. coli / Enterohemorrhagic E. coli | Hemorrhagic colitis, Hemolytic Uremic Syndrome (HUS) | Bloody diarrhea, severe abdominal cramps, minimal fever. Most common serotype: O157:H7 | **CONTRAINDICATED** ❌ | Antibiotics increase HUS risk by triggering toxin release; pooled OR approximately 1.33 (NS overall) to 2.24 (low-bias studies) per Freedman 2016 CID meta-analysis (PMID 26917812, n=1,896 across 17 studies). NO clinical benefit. | | **ETEC** | Enterotoxigenic E. coli | Traveler’s diarrhea, Watery diarrhea | Profuse watery diarrhea, abdominal cramps, low-grade fever. Leading cause of traveler’s diarrhea. | **YES** ✓ (Moderate-severe cases) | Shortens illness by 24-36 hours. Azithromycin or rifaximin preferred. | | **EPEC** | Enteropathogenic E. coli | Infantile diarrhea, Persistent diarrhea | Watery diarrhea in children \<2 years (developing countries). Causes attaching-effacing lesions. | **SELECTIVE** ⚠️ | Consider only if persistent \>2 weeks or severe. Most cases self-limited. | | **EAEC** | Enteroaggregative E. coli | Acute & chronic watery diarrhea, Traveler’s diarrhea | Watery diarrhea (can be persistent), low-grade fever. “Stacked brick” appearance on microscopy. | **SELECTIVE** ⚠️ | Evidence limited. Treat if moderate-severe or persistent. Similar to ETEC. | | **EIEC** | Enteroinvasive E. coli | Dysentery-like illness, Inflammatory colitis | Bloody/mucoid diarrhea, fever, severe cramps. Closely related to Shigella. Invades colonic epithelium. | **YES** ✓ (Severe cases) | Shortens duration and reduces complications. Treat like Shigella. | | **DAEC** | Diffusely Adherent E. coli | Watery diarrhea (questionable pathogenicity) | Watery diarrhea in children. Pathogenic role unclear and debated. | **NO** ❌ | Insufficient evidence of pathogenicity. Supportive care only. | | **UPEC** | Uropathogenic E. coli | Urinary tract infections (UTIs), Cystitis, Pyelonephritis | Dysuria, frequency, urgency, flank pain, fever (if pyelonephritis). Most common cause of UTIs. | **YES** ✓ | Standard UTI treatment. Fluoroquinolones, TMP-SMX, nitrofurantoin, or fosfomycin. | | **NMEC** | Neonatal Meningitis E. coli | Neonatal meningitis, Neonatal sepsis | Fever, lethargy, poor feeding in neonates. Possesses K1 capsule enabling CNS invasion. | **YES** ✓ | Critical. Requires IV cephalosporins (cefotaxime) + aminoglycosides. | | **APEC** | Avian Pathogenic E. coli | Avian colibacillosis (birds only) | Respiratory disease, septicemia in poultry. Not typically a human pathogen. | **N/A** | Veterinary pathogen. Not relevant to human medicine. | ------------------------------------------------------------------------ ## TABLE 2: INTESTINAL vs. EXTRAINTESTINAL E. COLI | **Category** | **Pathotypes Included** | **Primary Site** | **General Approach** | |----|----|----|----| | **Intestinal Pathogenic E. coli (InPEC)** | STEC/EHEC, ETEC, EPEC, EAEC, EIEC, DAEC | Gastrointestinal tract | Variable - depends on specific pathotype | | **Extraintestinal Pathogenic E. coli (ExPEC)** | UPEC, NMEC, APEC | Urinary tract, Blood, CNS, Respiratory (birds) | Generally requires antibiotics | ------------------------------------------------------------------------ ## TABLE 3: ANTIBIOTIC TREATMENT DECISION TABLE | **Pathotype** | **Treat with Antibiotics?** | **First-Line Agent(s)** | **Dosing** | **Key Pearl** | |----|----|----|----|----| | **STEC/EHEC** | **NO** - Contraindicated | None - Supportive care + IV hydration | N/A | IV hydration within 4 days reduces HUS risk. Monitor for HUS up to 14 days. | | **ETEC** | **YES** - If moderate-severe | Azithromycin (preferred) OR Rifaximin OR Ciprofloxacin | Azithromycin 500mg x 3d; Rifaximin 200mg TID x 3d | Drug of choice for traveler’s diarrhea. Shortens illness 24-36 hours. | | **EPEC** | **MAYBE** - If persistent \>2 weeks | Azithromycin OR TMP-SMX (children) | Azithromycin 10 mg/kg/day x 3d; TMP-SMX 5 mg/kg BID x 5d | Most cases self-limited. Common in developing countries. | | **EAEC** | **MAYBE** - If moderate-severe | Azithromycin (same as ETEC) | Azithromycin 500mg x 3d | Clinical significance debated. Often co-detected with other pathogens. | | **EIEC** | **YES** - If severe | Azithromycin OR Ceftriaxone | Azithromycin 500mg x 3d; Ceftriaxone 1g IV daily | Treat like Shigella - very similar organism. | | **DAEC** | **NO** | None - Supportive care only | N/A | Pathogenicity questionable. Rarely detected clinically. | | **UPEC** | **YES** - Always | Nitrofurantoin, Fosfomycin, TMP-SMX, Fluoroquinolones | Varies by drug and severity (cystitis vs pyelonephritis) | Uncomplicated cystitis: 3-5 days; Pyelonephritis: 7-14 days | | **NMEC** | **YES** - Critical emergency | Cefotaxime + Gentamicin (IV) | Cefotaxime 50 mg/kg Q8-12h + **Gentamicin extended-interval 4-5 mg/kg q24-48h** (per-gestational-age and per-postnatal-age dosing per Red Book / Neofax / NICU protocols) | High mortality without treatment. Requires LP and blood cultures. | ------------------------------------------------------------------------ ## TABLE 4: VIRULENCE FACTORS BY PATHOTYPE | **Pathotype** | **Key Virulence Factor(s)** | **Mechanism of Disease** | **Diagnostic Marker** | |----|----|----|----| | **STEC/EHEC** | Shiga toxin (Stx1, Stx2), LEE pathogenicity island, Intimin (eae) | Toxin inhibits protein synthesis → endothelial damage → HUS | Stx1/Stx2 genes by PCR; Toxin assay | | **ETEC** | Heat-labile toxin (LT), Heat-stable toxin (ST), Colonization factors | Toxins increase cAMP/cGMP → secretory diarrhea (cholera-like) | LT/ST genes by PCR | | **EPEC** | Bundle-forming pilus (BFP), Intimin (eae gene), LEE pathogenicity island | Attaching-effacing lesions → villous flattening → malabsorption | eae + bfpA genes (typical EPEC); eae only (atypical EPEC) | | **EAEC** | Aggregative adherence fimbriae (AAF), AggR regulon, EAST toxin | Forms biofilm on mucosa → persistent colonization and inflammation | AggR gene or AAF genes by PCR | | **EIEC** | Invasion plasmid antigens (Ipa), Similar to Shigella virulence | Invades colonic epithelium → inflammation, dysentery | ipaH gene by PCR (similar to Shigella) | | **UPEC** | P fimbriae, Type 1 fimbriae, Hemolysin, CNF1 toxin | Adhesion to uroepithelium → ascending infection → inflammation | Culture from urine; No specific virulence testing needed | | **NMEC** | K1 capsule, IbeA protein, S fimbriae | K1 capsule evades immune system → bacteremia → CNS invasion | K1 antigen detection; CSF culture | ------------------------------------------------------------------------ ## TABLE 5: INFECTIOUS DOSE & TRANSMISSION ROUTES | **Pathotype** | **Infectious Dose (CFU)** | **Primary Transmission Routes** | **Incubation Period** | |----|----|----|----| | **STEC/EHEC** | Very low (10-100) | Undercooked beef (especially ground), unpasteurized milk, contaminated water, petting zoos | 1-8 days (median 3-4 days) | | **ETEC** | High (10⁶-10⁸) | Contaminated food/water in developing countries, ice cubes, raw vegetables | 12-72 hours | | **EPEC** | Moderate (10⁶) | Contaminated food/water, person-to-person (daycare), fomites | 12-48 hours | | **EAEC** | Unknown (likely moderate) | Contaminated food/water, persistent environmental contamination | Variable (1-8 days) | | **EIEC** | Low-moderate (10²-10⁴) | Contaminated food/water, person-to-person fecal-oral, similar to Shigella | 12-72 hours | | **UPEC** | N/A (ascending infection) | Endogenous (from GI tract to urinary tract), sexual activity, catheterization | Variable | | **NMEC** | N/A (vertical transmission) | Maternal GI/vaginal colonization → neonatal infection during delivery | 0-7 days of life | ------------------------------------------------------------------------ ## TABLE 6: GEOGRAPHIC & EPIDEMIOLOGIC PATTERNS | **Pathotype** | **Geographic Distribution** | **Primary Age Groups Affected** | **Special Populations at Risk** | |----|----|----|----| | **STEC/EHEC** | Primarily developed countries (North America, Europe, Japan) | All ages, but HUS most common in children \<5 and elderly \>65 | Children, elderly, immunocompromised | | **ETEC** | Worldwide; endemic in developing countries | Adults (travelers from developed countries); Children in endemic areas | International travelers, military personnel | | **EPEC** | Developing countries (Sub-Saharan Africa, Asia, Latin America) | Infants and children \<2 years | Malnourished children, formula-fed infants | | **EAEC** | Worldwide distribution | All ages | HIV/AIDS patients (causes persistent diarrhea) | | **EIEC** | Developing countries; sporadic in developed countries | All ages | Travelers to endemic areas | | **UPEC** | Worldwide | Women (reproductive age), Elderly men (prostatic disease) | Diabetes, pregnancy, anatomic abnormalities, catheterized patients | | **NMEC** | Worldwide | Neonates (especially \<7 days) | Premature infants, prolonged rupture of membranes | ------------------------------------------------------------------------ ## TABLE 7: LABORATORY DIAGNOSIS | **Pathotype** | **Traditional Methods** | **Molecular Methods** | **Rapid Tests Available** | **Clinical Laboratory Availability** | |----|----|----|----|----| | **STEC/EHEC** | Culture on sorbitol-MacConkey agar (O157:H7 only) | PCR for Stx1/Stx2 genes | Shiga toxin EIA | High - Most labs test for STEC | | **ETEC** | Not routinely cultured | PCR for LT/ST genes | Limited | Low - Requires specialized molecular panels | | **EPEC** | Not routinely cultured | PCR for eae, bfpA genes | Limited | Low - Requires molecular GI panels | | **EAEC** | Not routinely cultured | PCR for AggR, AAF genes | Limited | Low - Requires molecular GI panels | | **EIEC** | Culture (lactose-negative on MacConkey) | PCR for ipaH gene | Limited | Low - Often missed; similar to Shigella | | **UPEC** | Standard urine culture | Not routinely needed | Urine dipstick (leukocyte esterase, nitrites) | High - Universally available | | **NMEC** | CSF culture, blood culture | PCR for K1 capsule | Blood culture (automated systems) | High - Standard neonatal sepsis workup | **Note:** Multiplex molecular GI panels (e.g., BioFire FilmArray GI Panel, BD MAX Enteric panels) now available in many reference labs and can detect ETEC, EPEC, EAEC, EIEC, and STEC simultaneously. ------------------------------------------------------------------------ ## TABLE 8: ANTIBIOTIC RESISTANCE PATTERNS (United States Data) | **Pathotype** | **High Resistance (\>20%)** | **Moderate Resistance (10-20%)** | **Low Resistance (\<10%)** | **Universally Susceptible** | |----|----|----|----|----| | **ETEC** | Ampicillin (40-70%), Tetracycline (30-50%) | TMP-SMX (10-30%), Fluoroquinolones (10-25%) | Azithromycin (\<5%) | Carbapenems, Tigecycline | | **EPEC** | Ampicillin (50-70%), TMP-SMX (30-45%) | Fluoroquinolones (5-15%), Cephalosporins (20-30%) | Azithromycin (\<5%) | Carbapenems, Fosfomycin, Amikacin, Colistin | | **EAEC** | Ampicillin (60-70%), Tetracycline (30-40%) | TMP-SMX (20-30%) | Azithromycin (\<10%) | Carbapenems | | **EIEC** | Variable (similar to Shigella) | Fluoroquinolones (regional variation) | Azithromycin, Ceftriaxone | Carbapenems | | **UPEC** | Ampicillin (40-50%), TMP-SMX (20-30% in some regions) | Fluoroquinolones (10-30%), 1st gen cephalosporins | Nitrofurantoin, Fosfomycin | Carbapenems | **ESBL-Producing E. coli:** - Prevalence: 10-40% depending on region and healthcare vs. community-acquired - Affects: EPEC, EAEC, ETEC, UPEC - Confers resistance to: All penicillins, cephalosporins (except cefepime in some cases), monobactams - Remains susceptible to: Carbapenems, tigecycline, colistin (last resort) ------------------------------------------------------------------------ ## CLINICAL DECISION ALGORITHMS ### Algorithm 1: Acute Diarrhea After Well Water Exposure Patient with diarrhea + well water exposure | ↓ Is diarrhea bloody? | ┌───────┴───────┐ | | YES NO | | ↓ ↓ STEC likely Watery diarrhea | | ↓ ↓ Order: Mild/self-limited? - Stool culture | - Shiga toxin ┌───┴───┐ | | While pending: YES NO - NO antibiotics | | - NO antimotility ↓ ↓ - IV hydration Supportive Moderate-severe? - Monitor HUS care only | ↓ Consider antibiotics: - Azithromycin 500mg x 3d - IF STEC RULED OUT ### Algorithm 2: Antibiotic Decision for Confirmed E. coli Pathotype Confirmed E. coli pathotype identified | ↓ Which pathotype? | ┌───────────┼───────────┐ | | | ↓ ↓ ↓ STEC/ ETEC/EAEC/ UPEC/ EHEC EIEC/EPEC NMEC | | | ↓ ↓ ↓ NO Risk stratify YES Antibiotics | Antibiotics | ↓ (Always) | Severe/persistent/ | high-risk patient? | | | ┌─────┴─────┐ | YES NO | | | | ↓ ↓ | Antibiotics Supportive | indicated care only | | └──────┴──────────────────→ Treatment complete ------------------------------------------------------------------------ ## CRITICAL TEACHING POINTS ### 1. **The STEC Exception - NEVER FORGET** **Why STEC is different:** - **ONLY** E. coli pathotype where antibiotics are **CONTRAINDICATED** - Antibiotics increase HUS risk; pooled OR approximately 1.33 (NS overall) to 2.24 (low-bias subgroup) per Freedman 2016 CID meta-analysis (PMID 26917812). The Wong 2000 NEJM single-cohort 14× estimate (PMID 10874060) was based on n=71 with only 9 antibiotic-treated and wide CI 2.9-70.7; the modern best estimate from the larger meta-analysis is closer to 2-fold. - Mechanism: **fluoroquinolones, TMP-SMX, and beta-lactams** cause bacterial lysis → Shiga toxin release → endothelial damage. **Azithromycin does NOT induce Stx and is being studied as STEC-safe therapy** (Ohara, McGannon). The blanket "even bacteriostatic" claim does not apply to azithromycin/rifaximin. **Mnemonic:** “STEC = STOP antibiotics” **What DOES work for STEC:** - Early IV hydration (within 4 days of symptom onset) - ONLY proven intervention - Close monitoring for HUS (daily CBC, BMP up to 14 days) - Avoid: Antibiotics, antimotility agents, NSAIDs **High-risk STEC features predicting HUS:** - Age \<5 years or \>65 years - High initial WBC count (\>15,000) - Stool culture positive early in illness - Stx2 (more virulent than Stx1) - Use of antibiotics ------------------------------------------------------------------------ ### 2. **Geographic & Travel Considerations** **ETEC - “Traveler’s Diarrhea”** - Most common cause of traveler’s diarrhea (30-40% of cases) - Endemic in: Latin America, Africa, South Asia, Middle East - Classic scenario: Tourist develops watery diarrhea 2 days into Mexico trip - Prevention: “Boil it, cook it, peel it, or forget it” - Prophylaxis: Generally NOT recommended (promote resistance) **EPEC - “Infantile Diarrhea in Developing Countries”** - After rotavirus, leading cause of death in children \<2 in developing countries - Rare in developed countries - Important consideration in adopted children from endemic areas - Associated with malnutrition and formula feeding (lack of protective maternal antibodies) **STEC - “The Burger Bug”** - Primarily developed countries (USA, Canada, UK, Japan, Germany) - Peak incidence: Summer months (BBQ season) - Outbreaks linked to: Ground beef, unpasteurized milk/juice, swimming pools, petting zoos - Cattle are asymptomatic reservoirs ------------------------------------------------------------------------ ### 3. **Antibiotic Resistance - Emerging Threats** **ESBL-Producing E. coli (20-40% of isolates in some areas):** - Confers resistance to most β-lactams (including 3rd generation cephalosporins) - Most common gene: blaCTX-M (CTX-M-15 predominates) - Risk factors: Recent hospitalization, nursing home residence, recent antibiotic use, international travel - Treatment: Carbapenems (ertapenem, meropenem) for severe infections **Fluoroquinolone Resistance (Rising globally):** - Campylobacter: 40% in some US regions, \>80% in Southeast Asia - ETEC: 10-25% in travelers returning from Asia - Treatment failure rates: 15-30% with ciprofloxacin for traveler’s diarrhea - Alternative: Azithromycin (maintains low resistance \<5%) **Why Azithromycin is increasingly preferred:** - Low resistance across all diarrheagenic E. coli (\<5%) - Safe in pregnancy and children - Once-daily dosing - Does NOT increase STEC toxin production (unlike fluoroquinolones) - Reduces fecal shedding (institutional benefit) ------------------------------------------------------------------------ ### 4. **Not All E. coli Are Equal** **Commensalism vs. Pathogenicity:** - ~10⁸-10⁹ E. coli CFU/gram in normal stool - \>99% of gut E. coli are BENEFICIAL or neutral - Produce vitamin K2, compete with pathogens, maintain gut homeostasis - Pathogenic E. coli require SPECIFIC virulence factors (toxins, adhesins, invasins) **Cannot distinguish by routine culture:** - All E. coli grow on MacConkey agar as pink/red (lactose-fermenting) colonies - Exception: EHEC O157:H7 (sorbitol-negative) and EIEC (lactose-negative) - Requires molecular testing (PCR) or immunoassays to identify pathotypes - Many labs only test for STEC; other pathotypes require specific multiplex panels **Clinical implication:** - Stool culture showing “normal flora including E. coli” does NOT rule out pathogenic E. coli - Must specifically order: STEC testing, GI pathogen panel, or send to reference lab ------------------------------------------------------------------------ ### 5. **Special Populations - Different Rules Apply** **Immunocompromised Patients (HIV, chemotherapy, transplant):** - EAEC → persistent diarrhea (weeks to months), wasting - Higher risk of bacteremia with any InPEC pathotype - More likely to need antibiotics even for typically self-limited infections - Consider empiric treatment while awaiting cultures **Neonates (\<28 days):** - NMEC → life-threatening meningitis/sepsis - ANY E. coli bacteremia in neonate warrants LP (20-30% have concurrent meningitis) - Empiric coverage must include E. coli (ampicillin + gentamicin OR cefotaxime) - High mortality (15-40%) even with appropriate treatment **Pregnant Women:** - UTIs (UPEC) progress to pyelonephritis more rapidly - Asymptomatic bacteriuria requires treatment (unlike non-pregnant women) - Increased risk of preterm labor with pyelonephritis - Antibiotic choices: Cephalexin, nitrofurantoin (avoid in 3rd trimester), fosfomycin - Avoid: Fluoroquinolones, TMP-SMX in 1st/3rd trimester **Elderly with Atherosclerosis:** - Non-typhoidal Salmonella (and E. coli) can seed atherosclerotic plaques - Risk of mycotic aneurysm, endovascular infection - Lower threshold to treat Salmonella bacteremia in elderly - May require prolonged antibiotics (4-6 weeks) ------------------------------------------------------------------------ ### 6. **Post-Infectious Complications - Think Beyond Acute Illness** **Hemolytic Uremic Syndrome (HUS) - STEC:** - Triad: Hemolytic anemia + Thrombocytopenia + Acute kidney injury - Occurs 5-10 days after diarrhea onset (as diarrhea resolving) - Most common cause of acute renal failure in children - 3-5% mortality, 12% develop ESRD, 25% have long-term renal sequelae - No specific treatment - supportive care, dialysis if needed - **Avoid platelet transfusions** unless life-threatening bleeding (may worsen thrombotic microangiopathy) **Reactive Arthritis (Reiter’s Syndrome):** - Follows EIEC, Shigella, Salmonella, Campylobacter infections - Classic triad: Arthritis + Urethritis + Conjunctivitis (“Can’t see, can’t pee, can’t climb a tree”) - Strongly associated with HLA-B27 - Onset: 1-3 weeks after GI infection resolves - Treatment: NSAIDs, sometimes DMARDs if persistent **Guillain-Barré Syndrome (GBS):** - Most commonly follows Campylobacter (but can follow other GI infections) - Molecular mimicry: Bacterial lipooligosaccharides cross-react with gangliosides in peripheral nerves - Onset: 1-3 weeks after infection - Ascending paralysis, areflexia, potential respiratory failure - Treatment: IVIG or plasmapheresis **Post-Infectious IBS (PI-IBS):** - Develops in 10-15% of patients after acute bacterial gastroenteritis - Risk factors: Female sex, younger age, severity of acute illness, psychological stress - Symptoms persist \>6 months after infection clears - Treatment: Standard IBS management (dietary, probiotics, antispasmodics) ------------------------------------------------------------------------ ### 7. **Laboratory Pearls - Optimizing Diagnosis** **When to order what:** | **Clinical Scenario** | **Test to Order** | **Rationale** | |----|----|----| | Bloody diarrhea | Stool culture + Shiga toxin assay (or STEC PCR) | MUST rule out STEC before giving antibiotics | | Watery diarrhea + fever | Stool culture for Salmonella, Shigella, Campylobacter | Standard bacterial pathogens | | Traveler’s diarrhea | Consider GI multiplex PCR panel | Detects ETEC, EAEC, parasites; faster than culture | | Persistent diarrhea (\>7 days) | GI multiplex panel + ova & parasites x3 | EPEC, EAEC, Giardia, Cryptosporidium | | HIV patient with chronic diarrhea | Comprehensive testing: GI panel, O&P, mycobacterial culture, CMV | Multiple opportunistic pathogens possible | | Outbreak investigation | Stool culture + save isolates for serotyping/PFGE | Need isolates for epidemiologic analysis | **Multiplex GI Panels (BioFire, Luminex, BD MAX):** - **Pros:** Rapid (1-2 hours), detects multiple pathogens simultaneously, high sensitivity - **Cons:** Expensive (\$200-400), may detect colonization vs. true infection, not all labs have - **What they detect:** STEC, ETEC, EPEC, EAEC, EIEC + Salmonella, Shigella, Campylobacter, viruses, parasites - **Clinical use:** Consider for severe illness, immunocompromised, outbreak, negative routine culture ------------------------------------------------------------------------ ### 8. **Supportive Care - Never Forget the Basics** **Hydration is the cornerstone:** - Prevents dehydration-related mortality (especially children, elderly) - Oral rehydration solution (ORS) preferred if patient can tolerate PO - WHO ORS formula: Na+ 75 mEq/L, glucose 75 mmol/L (promotes Na-glucose cotransport) - IV fluids if: Severe dehydration, hemodynamic instability, intractable vomiting, altered mental status **What NOT to do:** - Antimotility agents (loperamide, diphenoxylate) with bloody diarrhea or fever - Can precipitate toxic megacolon - Increase risk of HUS with STEC - Prolong illness with invasive pathogens (Shigella, EIEC) - Bismuth subsalicylate in children \<12 years (Reye’s syndrome risk) - NSAIDs in suspected STEC (may worsen renal injury) **Nutrition:** - Resume normal diet as soon as tolerated (including regular dairy if tolerated) - BRAT diet (bananas, rice, applesauce, toast) is outdated - insufficient calories/protein - Continue breastfeeding in infants - Small, frequent meals if nausea/cramping prominent **Probiotics:** - Evidence mixed; generally safe - Possible benefit: Lactobacillus GG, Saccharomyces boulardii - Do NOT give if immunocompromised (risk of fungemia with S. boulardii) ------------------------------------------------------------------------ ### 9. **Public Health & Reporting Requirements** **Reportable Conditions (varies by state, but commonly include):** - STEC/EHEC infection (ALL cases) - Hemolytic Uremic Syndrome - Shigellosis - Salmonellosis - Campylobacteriosis - Outbreaks (≥2 linked cases) **When to report:** - Suspicion is sufficient - definitive diagnosis NOT required - Report to local/state health department within 24-48 hours - Helps identify outbreaks, contaminated food sources, common exposures - Health department may require follow-up stool cultures to clear food handlers **High-risk occupations requiring clearance:** - Food handlers - Healthcare workers (direct patient care) - Daycare workers - Usually require 2 negative stool cultures ≥24 hours apart, ≥48 hours after antibiotic completion ------------------------------------------------------------------------ ### 10. **Prevention Strategies - Patient Counseling** **For patients with well water:** - Annual testing for coliforms (minimum) - Test more frequently if: Nearby contamination, heavy rain/flooding, pregnant/infant in home - Shock chlorination after positive result - Consider UV treatment or filtration system - Safe distance: Well ≥50 feet from septic system, livestock **Food safety:** - Cook ground beef to 160°F (71°C) - use meat thermometer - Avoid raw milk and raw milk products - Wash produce thoroughly, especially leafy greens - Separate cutting boards for raw meat and produce - Refrigerate promptly (\<2 hours, \<1 hour if \>90°F) **Travel advice (ETEC prevention):** - “Boil it, cook it, peel it, or forget it” - Avoid: Ice, tap water, raw vegetables, street food, buffets - Safe: Bottled water (sealed), hot coffee/tea, beer, wine, freshly cooked food - Consider taking azithromycin or rifaximin for self-treatment (not prophylaxis) - Prophylactic antibiotics NOT routinely recommended (promotes resistance) ------------------------------------------------------------------------ ## SUMMARY: KEY DECISION POINTS ### When Patient Has Diarrhea + Well Water Exposure: **1. Is it bloody diarrhea?** - **YES** → Suspect STEC → **DO NOT give antibiotics** → Order Shiga toxin test + culture - **NO** → Continue evaluation **2. Is there fever or severe illness?** - **YES** → Consider bacterial pathogen → Order stool culture - **NO** → Likely viral or mild bacterial → Supportive care **3. Is STEC ruled out (negative Shiga toxin + culture)?** - **YES** → Can consider antibiotics if indicated by pathogen/severity - **NO** → Continue to withhold antibiotics **4. Which pathogen is identified?** - **Shigella** → Give antibiotics (azithromycin) - **Campylobacter** → Risk stratify → Give if high-risk - **Salmonella** → Risk stratify → Usually no antibiotics unless high-risk - **ETEC/EAEC/EIEC/EPEC** → Assess severity → Consider antibiotics if moderate-severe **5. Patient is asymptomatic but worried about exposure?** - **NO prophylactic antibiotics** - Education about symptoms to watch for - Reassurance that most exposures don’t cause illness ------------------------------------------------------------------------ ## REFERENCES & RESOURCES **Guidance:** [IDSA2017 infectious diarrhea guideline](https://pubmed.ncbi.nlm.nih.gov/29053792/); [CDC information for clinicians](https://www.cdc.gov/ecoli/hcp/guidance/index.html). **Useful Websites:** - CDC E. coli Information: www.cdc.gov/ecoli - Travelers’ Health (Traveler’s Diarrhea): wwwnc.cdc.gov/travel - State Health Department Well Water Testing Resources **Continuing Education:** - ID Board Review Courses (IDSA, Mayo Clinic) - CDC Laboratory Training Courses - APHL (Association of Public Health Laboratories) Resources ------------------------------------------------------------------------ ## ACRONYMS & ABBREVIATIONS - **AAF** = Aggregative Adherence Fimbriae - **APEC** = Avian Pathogenic E. coli - **BFP** = Bundle-Forming Pilus - **CFU** = Colony Forming Units - **DAEC** = Diffusely Adherent E. coli - **EAEC** = Enteroaggregative E. coli - **EHEC** = Enterohemorrhagic E. coli - **EIEC** = Enteroinvasive E. coli - **EPEC** = Enteropathogenic E. coli - **ESBL** = Extended-Spectrum Beta-Lactamase - **ETEC** = Enterotoxigenic E. coli - **ExPEC** = Extraintestinal Pathogenic E. coli - **GBS** = Guillain-Barré Syndrome - **HUS** = Hemolytic Uremic Syndrome - **InPEC** = Intestinal Pathogenic E. coli - **LEE** = Locus of Enterocyte Effacement - **LT** = Heat-Labile Toxin - **NMEC** = Neonatal Meningitis E. coli - **ORS** = Oral Rehydration Solution - **PI-IBS** = Post-Infectious Irritable Bowel Syndrome - **ST** = Heat-Stable Toxin - **STEC** = Shiga Toxin-Producing E. coli - **Stx** = Shiga Toxin - **TMP-SMX** = Trimethoprim-Sulfamethoxazole - **UPEC** = Uropathogenic E. coli - **UTI** = Urinary Tract Infection ------------------------------------------------------------------------ ## DOCUMENT INFORMATION **Created:** 2025 **Purpose:** Physician reference for E. coli pathotype classification and treatment **Based on:** Iowa well water contamination exposure case discussion **Evidence Level:** Based on CDC guidelines, IDSA guidelines, and peer-reviewed literature **Last Updated:** October 2025 ------------------------------------------------------------------------ *This document is intended for educational purposes for healthcare professionals. Clinical decisions should be individualized based on patient presentation, local epidemiology, and resistance patterns.* ## Related Notes - management enterococcal IE on HD - shared tags: antibiotic, clinical-medicine, gi - Nephro Ed Circle Map Text Summary - shared tags: antibiotic, gi - Lupus Nephritis Patient Handout - shared tags: clinical-medicine, infection - hyponatremia Factors Predisposing to Rapid Correction of Hyponatremia hepta - shared tags: clinical-medicine, gi - comprehensive guide CME - shared tags: clinical-medicine, gi - uti comprehensive report with urobiome - shared tags: antibiotic, clinical-medicine, gi - Nephrotic Diseases hepta - shared tags: clinical-medicine, infection - clinical rotation form content - shared tags: clinical-medicine, gi - hepatology report expanded references - shared tags: clinical-medicine, gi - NDOU AKI Without Hydronephrosis Review - shared tags: clinical-medicine, gi --- [Website version](https://urinenephrology.org/case-reports/ecoli-pathotypes-treatment.html) · Markdown synchronized October 3, 2026.